United States Biotechnology & Medical Research

Relay Therapeutics Inc (RLAY)

Track

Over the past 90 days, Relay Therapeutics Inc. insiders have executed 24 transactions, all of which were sales totaling approximately $24.97 million. These divestments, involving directors and executives, occurred amid a 54.3% increase in the stock price. No insider purchases were recorded during this period, following the company's most recent results financiers report in August 2026.
Ticker: RLAY Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Relay Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 4 Aug 2026
Value US$272,770.94 | Price 244.94 | Shares 79,451
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-04 2026-08-04 PrS Proposed sale
SEKAR KATHIRESAN

Director

Non-Executive Director
79,451
244.94
US$272,771 		79,451 244.94 US$272,771
2026-07-31 2026-07-31 PrS Proposed sale
SEKAR KATHIRESAN

Director

Non-Executive Director
68,998
168.24
US$1,576,086 		68,998 168.24 US$1,576,086
2026-07-30 2026-07-28 S Sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
82,970 -23.4%
213.70
US$2,432,961 		82,970 -23.4% 213.70 US$2,432,961
2026-07-30 2026-07-28 S Sale
3.2
Rahmer Peter

See remarks

Officer
1,000 -0.3%
18.61
US$100,000 		1,000 -0.3% 18.61 US$100,000
2026-07-30 2026-07-28 S Sale
3.3
Bergstrom Donald A

President, R&D

Officer
1,000 -0.5%
18.61
US$100,000 		1,000 -0.5% 18.61 US$100,000
2026-07-21 2026-07-21 PrS Proposed sale
SEKAR KATHIRESAN

Director

Non-Executive Director
1,000
19.81
US$100,000 		1,000 19.81 US$100,000
2026-07-20 2026-07-20 PrS Proposed sale
SEKAR KATHIRESAN

Director

Non-Executive Director
1,000
19.58
US$100,000 		1,000 19.58 US$100,000
2026-07-08 2026-07-07 PlS Planned sale
2.5
Patel Sanjiv

President and CEO

Executive Director
48,199 -7.3%
19.58
US$943,736 		48,199 -7.3% 19.58 US$943,736
2026-07-07 2026-07-07 PrS Proposed sale
2.5
SANJIV PATEL

Director; Officer

Executive Director
144,597
18.90
US$2,732,883 		144,597 18.90 US$2,732,883
2026-07-08 2026-07-06 PlS Planned sale
3.3
Bergstrom Donald A

President, R&D

Officer
8,660 -2.1%
18.71
US$162,029 		8,660 -2.1% 18.71 US$162,029
2026-07-08 2026-07-06 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
17,717 -10.0%
18.69
US$331,131 		17,717 -10.0% 18.69 US$331,131
2026-07-02 2026-06-30 PlS Planned sale
3.2
Rahmer Peter

See remarks

Officer
50,000 -18.1%
19.09
US$954,500 		50,000 -18.1% 19.09 US$954,500
2026-06-30 2026-06-30 PrS Proposed sale
3.2
PETER RAHMER

Officer

Officer
50,000
19.74
US$987,000 		50,000 19.74 US$987,000
2026-06-24 2026-06-22 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
51,560 -22.5%
16.97
US$874,973 		51,560 -22.5% 16.97 US$874,973
2026-06-24 2026-06-22 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
61,563 -25.8%
16.97
US$1,044,724 		61,563 -25.8% 16.97 US$1,044,724
2026-06-24 2026-06-22 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
56,323 -24.1%
16.97
US$955,801 		56,323 -24.1% 16.97 US$955,801
2026-06-24 2026-06-22 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
17,717 -9.1%
17.01
US$301,366 		17,717 -9.1% 17.01 US$301,366
2026-06-24 2026-06-22 PlS Planned sale
3.3
Bergstrom Donald A

President, R&D

Officer
93,456 -18.3%
16.94
US$1,583,145 		93,456 -18.3% 16.94 US$1,583,145
2026-06-22 2026-06-22 PrS Proposed sale
3.3
DONALD BERGSTROM

Officer

Officer
110,646
15.88
US$1,757,058 		110,646 15.88 US$1,757,058
2026-06-22 2026-06-22 PrS Proposed sale
3.3
DONALD BERGSTROM

Officer

Officer
110,646
15.88
US$1,757,058 		110,646 15.88 US$1,757,058
2026-06-22 2026-06-22 PrS Proposed sale
3.4
THOMAS CATINAZZO

Officer

Officer
204,880
15.88
US$3,253,494 		204,880 15.88 US$3,253,494
2026-06-22 2026-06-22 PrS Proposed sale
3.4
THOMAS CATINAZZO

Officer

Officer
204,880
15.88
US$3,253,494 		204,880 15.88 US$3,253,494
2026-05-14 2026-05-14 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
17,717 -8.3%
12.86
US$227,841 		17,717 -8.3% 12.86 US$227,841
2026-05-14 2026-05-14 PrS Proposed sale
3.4
THOMAS CATINAZZO

Officer

Officer
37,234
13.22
US$492,233 		37,234 13.22 US$492,233
2026-04-30 2026-04-28 S Sale
3.3
Bergstrom Donald A

President, R&D

Officer
1,490 -0.4%
14.79
US$22,037 		1,490 -0.4% 14.79 US$22,037
2026-04-30 2026-04-28 S Sale
3.2
Rahmer Peter

See remarks

Officer
753 -0.3%
14.79
US$11,137 		753 -0.3% 14.79 US$11,137
2026-04-30 2026-04-28 S Sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
972 -0.5%
14.79
US$14,376 		972 -0.5% 14.79 US$14,376
2026-04-09 2026-04-09 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
1,800 -0.8%
15.00
US$27,000 		1,800 -0.8% 15.00 US$27,000
2026-04-09 2026-04-07 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
17,717 -7.7%
13.01
US$230,498 		17,717 -7.7% 13.01 US$230,498
2026-03-11 2026-03-09 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
17,717 -7.1%
10.06
US$178,233 		17,717 -7.1% 10.06 US$178,233
2026-03-09 2026-03-09 PrS Proposed sale
3.4
THOMAS CATINAZZO

Officer

Officer
53,151
9.89
US$525,663 		53,151 9.89 US$525,663
2026-01-29 2026-01-28 S Sale
3.3
Bergstrom Donald A

President, R&D

Officer
2,686 -0.6%
8.45
US$22,697 		2,686 -0.6% 8.45 US$22,697
2026-01-29 2026-01-28 S Sale
3.2
Rahmer Peter

See remarks

Officer
1,354 -0.5%
8.45
US$11,441 		1,354 -0.5% 8.45 US$11,441
2026-01-29 2026-01-28 S Sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
1,695 -0.7%
8.45
US$14,323 		1,695 -0.7% 8.45 US$14,323
2026-01-29 2026-01-27 S Sale
3.3
Bergstrom Donald A

President, R&D

Officer
18,895 -4.3%
7.62
US$143,980 		18,895 -4.3% 7.62 US$143,980
2026-01-29 2026-01-27 S Sale
3.2
Rahmer Peter

See remarks

Officer
11,684 -4.0%
7.62
US$89,032 		11,684 -4.0% 7.62 US$89,032
2026-01-29 2026-01-27 S Sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
13,820 -5.2%
7.62
US$105,308 		13,820 -5.2% 7.62 US$105,308
2026-01-07 2026-01-06 S Sale
2.5
Patel Sanjiv

President and CEO

Executive Director
43,168 -6.1%
7.82
US$337,574 		43,168 -6.1% 7.82 US$337,574
2025-11-04 2025-11-03 S Sale
2.5
Patel Sanjiv

President and CEO

Executive Director
62,073 -8.1%
7.00
US$434,511 		62,073 -8.1% 7.00 US$434,511
2025-10-30 2025-10-29 S Sale
3.2
Rahmer Peter

See remarks

Officer
21,394 -6.0%
7.50
US$160,455 		21,394 -6.0% 7.50 US$160,455
2025-10-29 2025-10-29 PrS Proposed sale
3.2
Peter J Rahmer

Officer

Officer
21,394
7.50
US$160,436 		21,394 7.50 US$160,436
2025-10-30 2025-10-28 S Sale
3.2
Rahmer Peter

See remarks

Officer
19,135 -5.1%
7.29
US$139,494 		19,135 -5.1% 7.29 US$139,494
2025-10-30 2025-10-28 S Sale
3.3
Bergstrom Donald A

President, R&D

Officer
30,897 -5.6%
7.29
US$225,239 		30,897 -5.6% 7.29 US$225,239
2025-10-30 2025-10-28 S Sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
21,664 -6.5%
7.29
US$157,931 		21,664 -6.5% 7.29 US$157,931
2025-07-10 2025-07-09 S Sale
2.5
Patel Sanjiv

President and CEO

Executive Director
18,639 -2.4%
3.57
US$66,541 		18,639 -2.4% 3.57 US$66,541
2025-07-10 2025-07-09 S Sale
2.5
Patel Sanjiv

President and CEO

Executive Director
42,740 -5.2%
3.57
US$152,582 		42,740 -5.2% 3.57 US$152,582
2025-04-30 2025-04-30 S Sale
3.3
Bergstrom Donald A

President, R&D

Officer
27,472 -4.5%
3.00
US$82,416 		27,472 -4.5% 3.00 US$82,416
2025-04-30 2025-04-30 S Sale
3.2
Rahmer Peter

See remarks

Officer
10,739 -2.7%
3.00
US$32,217 		10,739 -2.7% 3.00 US$32,217
2025-04-30 2025-04-30 S Sale
4.3
Adams Brian

Chief Legal Officer

Officer
12,943 -3.2%
3.00
US$38,829 		12,943 -3.2% 3.00 US$38,829
2025-04-30 2025-04-30 S Sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
12,943 -3.5%
3.00
US$38,829 		12,943 -3.5% 3.00 US$38,829
2025-04-30 2025-04-29 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
3,558 -1.0%
3.23
US$11,492 		3,558 -1.0% 3.23 US$11,492
2025-04-29 2025-04-29 PrS Proposed sale
3.4
THOMAS J CATINAZZO

Officer

Officer
3,558
3.23
US$11,492 		3,558 3.23 US$11,492
2025-04-30 2025-04-28 S Sale
3.3
Bergstrom Donald A

President, R&D

Officer
4,090 -0.7%
3.17
US$12,965 		4,090 -0.7% 3.17 US$12,965
2025-04-30 2025-04-28 S Sale
3.2
Rahmer Peter

See remarks

Officer
1,364 -0.3%
3.17
US$4,324 		1,364 -0.3% 3.17 US$4,324
2025-04-30 2025-04-28 S Sale
4.3
Adams Brian

Chief Legal Officer

Officer
1,644 -0.4%
3.17
US$5,211 		1,644 -0.4% 3.17 US$5,211
2025-04-30 2025-04-28 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
981 -0.3%
3.17
US$3,110 		981 -0.3% 3.17 US$3,110
2025-04-30 2025-04-28 S Sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
1,709 -0.5%
3.17
US$5,418 		1,709 -0.5% 3.17 US$5,418
2025-04-28 2025-04-28 PrS Proposed sale
3.4
THOMAS J CATINAZZO

Officer

Officer
981
3.17
US$3,110 		981 3.17 US$3,110
2025-04-24 2025-04-23 S Sale
2.5
Patel Sanjiv

President and CEO

Executive Director
18,653 -2.2%
2.97
US$55,399 		18,653 -2.2% 2.97 US$55,399
2025-04-24 2025-04-23 S Sale
2.5
Patel Sanjiv

President and CEO

Executive Director
42,769 -4.8%
2.97
US$127,024 		42,769 -4.8% 2.97 US$127,024
2025-03-31 2025-03-27 S Sale
3.2
Rahmer Peter

See remarks

Officer
247 -0.1%
2.84
US$701 		247 -0.1% 2.84 US$701
2025-03-31 2025-03-27 S Sale
3.3
Bergstrom Donald A

President, R&D

Officer
986 -0.2%
2.84
US$2,800 		986 -0.2% 2.84 US$2,800
2025-03-31 2025-03-27 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
4,566 -1.2%
2.84
US$12,967 		4,566 -1.2% 2.84 US$12,967
2025-03-31 2025-03-27 S Sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
298 -0.1%
2.84
US$846 		298 -0.1% 2.84 US$846
2025-03-31 2025-03-27 S Sale
4.3
Adams Brian

Chief Legal Officer

Officer
298 -0.1%
2.84
US$846 		298 -0.1% 2.84 US$846
2025-03-27 2025-03-27 PrS Proposed sale
3.4
THOMAS J CATINAZZO

Officer

Officer
4,566
2.84
US$12,967 		4,566 2.84 US$12,967
2025-02-13 2025-02-13 S Sale
2.5
Patel Sanjiv

President and CEO

Executive Director
75,324 -7.9%
3.70
US$278,699 		75,324 -7.9% 3.70 US$278,699
2025-02-13 2025-02-11 S Sale
2.5
Patel Sanjiv

President and CEO

Executive Director
140,182 -18.3%
3.85
US$539,701 		140,182 -18.3% 3.85 US$539,701
2025-01-30 2025-01-30 S Sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
20,791 -5.2%
4.42
US$91,896 		20,791 -5.2% 4.42 US$91,896
2025-01-30 2025-01-30 S Sale
3.2
Rahmer Peter

See remarks

Officer
17,250 -4.1%
4.42
US$76,245 		17,250 -4.1% 4.42 US$76,245
2025-01-30 2025-01-30 S Sale
4.3
Adams Brian

Chief Legal Officer

Officer
20,791 -4.9%
4.42
US$91,896 		20,791 -4.9% 4.42 US$91,896
2025-01-30 2025-01-30 S Sale
3.3
Bergstrom Donald A

President, R&D

Officer
30,823 -4.8%
4.42
US$136,238 		30,823 -4.8% 4.42 US$136,238
2025-01-30 2025-01-29 PlS Planned sale
3.4
Catinazzo Thomas

Chief Financial Officer

Officer
2,109 -0.5%
4.55
US$9,596 		2,109 -0.5% 4.55 US$9,596
2025-01-30 2025-01-29 S Sale
3.2
Rahmer Peter

See remarks

Officer
26,541 -5.9%
4.55
US$120,762 		26,541 -5.9% 4.55 US$120,762
2025-01-30 2025-01-29 S Sale
3.3
Bergstrom Donald A

President, R&D

Officer
46,407 -6.7%
4.55
US$211,152 		46,407 -6.7% 4.55 US$211,152
Explore more

More insider trading research around Relay Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America